CTI.L Regulatory News (CTI)

Cathay International Holdings Limited

("Cathay" or "the Company")

Notice of Interim Results 2013

Hong Kong, 19 August 2013 - Cathay International Holdings Limited (LSE: CTI.L), a main market listed investment holding company and leading investor in the growing healthcare sector in the People's Republic of China, today announces that the Company will issue its Interim Results for the six months ended 30 June 2013 on Friday 30 August 2013.

-END-

For further enquiries, please contact:

About Cathay

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and a leading investor in the growing healthcare sector in the People's Republic of China ("PRC"). Taking advantage of the strong and growing domestic demand for high quality healthcare products in China, Cathay aims to identify investment opportunities with emphasis on high growth healthcare markets and build them into market sector leaders, with a clear exit strategy. Cathay has already demonstrated a strong track record of identifying high-growth potential investment opportunities in this area including: Lansen Group, China's leading specialty pharmaceutical company focused on rheumatology, Haotian Group, a company engaged in the manufacture, marketing and sale of key active ingredients for healthcare products, including dietary supplement inositol and Botai, a company engaged in the development of pharmaceutical products and bringing these to the growing Chinese market.

The Group employs more than 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a private equity investment arm focused on minority investment opportunities and a hotel investment.

For more information please visit the Company's website: www.cathay-intl.com.hk